Goldman Sachs forecasts Biohaven shares could surge nearly 100%, citing the company's promising pipeline for kidney disease treatments and a $23 price target.
#YonhapInfomax #GoldmanSachs #Biohaven #PriceTarget #KidneyDisease #BiotechPipeline #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=104493